Verano Holdings (VRNO) Non Operating Investment Income (2022)
Verano Holdings' (VRNO) quarterly Non Operating Investment Income came in at $175000.0 in Q3 2022, up 202.34% on a QoQ basis from -$171000.0 in Q2 2022.
Verano Holdings (VRNO) Non Operating Investment Income (2022) Analysis & Trends
Verano Holdings (VRNO) has 1 years of Non Operating Investment Income data on file, last reported at $175000.0 in Q3 2022.
- On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to $175000.0 in Q3 2022; TTM through Jun 2023 was $175000.0, a 105.23% increase from a year earlier, with the FY2022 full-year figure at $14.1 million, changed N/A from the prior year.
- Non Operating Investment Income for Q3 2022 stood at $175000.0, up from -$171000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for VRNO reached as high as $175000.0 in Q3 2022 and fell as low as -$3.2 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Verano Holdings | 1.99 Bn | 1.91 Bn | 98.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 175,000.00 |
| Sep 30, 2022 | 175,000.00 |
| Jun 30, 2022 | -171,000.00 |
| Jun 30, 2022 | -171,000.00 |
| Mar 31, 2022 | -3.18 Mn |
| Mar 31, 2022 | -3.18 Mn |